

PATIENT-LAST-NAME, FIRST-NAME I.

Date of Birth: 01-Jan-1950

Gender: Male


Report Number: OR000123456-4044

Report Date: 30-Oct-2017

Ordering Physician: Dr. I. Ordering

Recurrence Score[®] Result

High
48



What does a Recurrence Score of 48 mean?


Based on your patient's Recurrence Score of 48, your patient's risk of recurrence within 3 years of surgery alone is **20%** for a T3 tumor, or 34% for a T4 tumor.

Your patient's risk of recurrence within 5 years of adjuvant 5FU/LV is **17%**. The risk of recurrence will likely decrease by 4% with the addition of oxaliplatin.

Recurrence Risk After Surgery (PROGNOSIS)

QUASAR Study

3-Year Risk of Recurrence by T-Stage



This graph shows the 3-year risk of recurrence by Recurrence Score result and T-stage in MMR-P patients following surgery alone, based on the results of the QUASAR validation study.¹ Based on this study, patients with higher Recurrence Score results are likely to have a greater absolute benefit from chemotherapy.

In the parent QUASAR trial, patients randomized to receive chemotherapy after surgery had an estimated 20% relative reduction of cancer recurrence.²

20%

T3, MMR-P

95% CI: 16% - 26%

34%

T4, MMR-P

95% CI: 24% - 46%

Impact of Nodes Assessed: For patients with ≥ 12 nodes examined the 3-year recurrence risk was lower than that shown in the Figure. For T3 MMR-P patients, the absolute reduction in risk ranged from 2% for low to 6% for higher Recurrence Score results. For T4 MMR-P patients, the reduction in risk ranges from 4% to 10%, respectively.

Information on the Colon Recurrence Score and clinical experience is available upon request.

PATIENT-LAST-NAME, FIRST-NAME I.

Date of Birth: **01-Jan-1950** Gender: **Male** Report Number: **OR000123456-4044** Report Date: **30-Oct-2017**
 Ordering Physician: **Dr. I. Ordering**

Medical Record/Patient #: **1234567-01**

Specimen Source/ID: **Colon/SP-16_0123456**

Date of Collection: **15-Oct-2017**

Specimen Received: **17-Oct-2017**


Additional Recipient: **Dr. I. Additional**

Pathologist: **Dr. I. Pathologist**

Recurrence Risk After Chemotherapy (PROGNOSIS)

NSABP C-07 Study

5-Year Risk of Recurrence +/- Oxaliplatin



This graph shows the 5-year risk of recurrence by Recurrence Score result for patients treated with 5FU/LV chemotherapy and 5FU/LV + oxaliplatin, based on the results in the NSABP C-07 study, which randomized patients to 5FU/LV or 5FU/LV + oxaliplatin.³

Based on this study, patients with higher Recurrence Score results are likely to have a greater absolute benefit from the addition of oxaliplatin to 5FU/LV.

17%

5-FU/LV

95% CI: 12% - 24%

13%

5-FU/LV+OXA

95% CI: 9% - 19%

References:

1. Gray et al. *J Clin Oncol*. 2011.
2. Gray et al. *Lancet*. 2007.
3. Yothers et al. *J Clin Oncol*. 2013.

Laboratory Director(s): S. Shak, MD; F. Baehner, MD; H. Bailey, MD & P. Joseph, MD

This test was developed and its performance characteristics determined by Genomic Health, Inc. It has not been cleared or approved by the FDA, nor is it currently required to be. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.



Genomic Health, Inc.
 301 Penobscot Drive, Redwood City, CA 94063 USA
 +1.866.ONCOTYPE (+1.866.662.6897)
www.oncotypedx.com/contact
 CLIA Number 05D1018272

PATIENT-LAST-NAME, FIRST-NAME I.

Date of Birth: 01-Jan-1950

Gender: Male


Report Number: OR000123456-4044

Report Date: 30-Oct-2017

Ordering Physician: Dr. I. Ordering

Patient Educational Summary


What does your result mean?



Your Recurrence Score of 48 indicates a **20%** risk of your tumor returning within 3 years of your surgery alone without chemotherapy.

By measuring the activity of certain genes in your colon tumor tissue, the Oncotype DX test predicts the risk of your cancer returning within 3 years - a key factor in deciding your treatment options after surgery.

What are the chances of your colon cancer returning?



Based on the QUASAR validation study, if 100 people with a Recurrence Score result of **48** are treated with surgery and no chemotherapy:

 **80 people**

Will **not** have their colon cancer return within 3 years.

 **20 people**

Will have their colon cancer return within 3 years.

What are your treatment options? (For doctor/patient discussion)



FOLLOW-UP



CHEMOTHERAPY

Join other colon cancer patients to learn about genomics and help transform patient care: MyOncotype.com

This Patient Educational Summary is a brief explanation of your Oncotype DX test results. It is being provided by your doctor for discussion purposes. More information at www.OncotypeQ.com.